非刚性三维校正肝脏MR动态减影技术应用于肝细胞癌经导管动脉内化疗栓塞术后疗效评估的研究

doi:10.3877/cma.j.issn.1674-0793.2015.05.014

中华普通外科学文献(电子版) ›› 2015, Vol. 09 ›› Issue (05) : 382 -388. doi: 10.3877/cma.j.issn.1674-0793.2015.05.014

所属专题：专题评论；文献；

论著

非刚性三维校正肝脏MR动态减影技术应用于肝细胞癌经导管动脉内化疗栓塞术后疗效评估的研究

王猛¹, 蔡华崧¹, 高进云², 朱莹¹, 张永裕³, 黄梦琪¹, 辛丽丽⁴, 冯仕庭¹^,^†(

)

^1. 510080　广州，中山大学附属第一医院放射诊断专科
^2. 518033　深圳市中医院放射影像科
^3. 510080　广州，中山大学附属第一医院放射介入专科
^4. 262100　山东省安丘市妇幼保健院超声科

收稿日期:2015-07-05 出版日期:2015-10-01
通信作者: 冯仕庭

Application of non rigid 3D-registration for accurate subtraction of dynamic liver MR imaging technique in tumor blood supply assessment for hepatocellular carcinoma after transarterial chemoembolization

Meng Wang¹, Huasong Cai¹, Jinyun Gao², Ying Zhu¹, Yongyu Zhang³, Mengqi Huang¹, Lili Xin⁴, Shiting Feng¹^,^†()

^1. Department of Diagnostic Radiology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
^2. Department of Radiology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518033, China
^3. Department of Interventional Radiology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
^4. Department of Ultrasonography, Anqiu Maternal and Child Hygiene Hospital, Anqiu 262100, China

Received:2015-07-05 Published:2015-10-01
Corresponding author: Shiting Feng
About author:
Corresponding author: Feng Shiting, Email: fst1977@163.com

全文 ( ) 下载PDF ( ) 导出引用

引用本文：

王猛, 蔡华崧, 高进云, 朱莹, 张永裕, 黄梦琪, 辛丽丽, 冯仕庭. 非刚性三维校正肝脏MR动态减影技术应用于肝细胞癌经导管动脉内化疗栓塞术后疗效评估的研究[J/OL]. 中华普通外科学文献(电子版), 2015, 09(05): 382-388.

Meng Wang, Huasong Cai, Jinyun Gao, Ying Zhu, Yongyu Zhang, Mengqi Huang, Lili Xin, Shiting Feng. Application of non rigid 3D-registration for accurate subtraction of dynamic liver MR imaging technique in tumor blood supply assessment for hepatocellular carcinoma after transarterial chemoembolization[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2015, 09(05): 382-388.

目的

对比CT增强和非刚性三维校正肝脏MR增强动态减影技术对肝细胞癌(HCC)经导管动脉内化疗栓塞术(TACE)后肿瘤血供判断能力的差异,探讨非刚性三维校正肝脏MR增强动态减影技术的临床应用价值。

方法

收集HCC患者TACE术后并再次需进行TACE治疗的病例21例,所有患者均行CT平扫及增强扫描、MR平扫及动态增强扫描,MR扫描采用非刚性三维校正动态减影技术。分别在CT和MR增强非刚性三维校正减影图像上对病灶血供情况评估统计,以再次TACE术前的DSA评价结合结节前后的体积变化综合考虑作为金标准,比较两种检查方式对碘油沉积病灶血供评价的能力。

结果

共分析126个碘油沉积灶,在对碘油沉积灶血供的判断中,CT与DSA检查诊断结果不一致(P<0.001),MR和DSA检查诊断结果一致(P=0.375);在结节的血供判断方面,CT/MR对肝结节血供判断的敏感度、特异度、假阳性率、假阴性率、正确指数、阳性似然比、阴性似然比、符合率分别为6.2%/99.1%、76.0%/69.2%、23.1%/30.8%、93.8%/0.9%、0.02/0.68、0.27/3.22、1.22/0.01、13.5%/96.0%。

结论

相对CT检查,非刚性三维校正肝脏MR动态减影技术在HCC患者TACE治疗后疗效评估中有明显的诊断优势,具有重要的临床应用价值。

关键词: CT, MRI, 减影, DSA, TACE

Objective

To compare the capacity between contrast-enhanced computed tomography (CT) and non rigid 3D-registration for accurate subtraction of dynamic liver magnetic resonance imaging (MRI) in tumor blood supply assessment for hepatocellular carcinoma(HCC) after transarterial chemoembolization(TACE), and to evaluate the clinical value of 3D-registration for accurate subtraction of dynamic liver magnetic resonance imaging(MRI).

Methods

Twenty-one patients with HCC followed TACE therapy were included in the study. All the patients underwent both contrast-enhanced CT and MRI. MRI examination used non rigid 3D-registration for accurate subtraction of dynamic liver imaging technique. And the assessment statistics of these patients’ blood supply information of all the lesions both in the CT images and the MRI image that dealt with non rigid 3D-registration were collected. Digital subtraction angiography (DSA) assessment before next TACE therapy and volume changes of the nodule were considered as the golden standard to compare the ability of tumor blood supply assessment of the two methods.

Results

One hundred and twenty-six lipiodol accumulation lesions were analyzed. The diagnostic accuracy was different between CT and DSA (P<0.001) while no difference between MR and DSA (P=0.375) of all the lipiodol accumulation lesion’s blood supply. In the assessment of lesion’s blood supply, the sensitivity, specificity, false positive rate, false negative rate, correct indices, positive likelihood ratio, negative likelihood ratio and coincidence rate of CT/MR were 6.2%/99.1%, 76.0%/69.2%, 23.1%/30.8%, 93.8%/0.9%, 0.02/0.68, 0.27/3.22, 1.22/0.01, 13.5%/96.0%.

Conclusion

Non rigid 3D-registration for accurate subtraction of dynamic liver magnetic resonance imaging is superior in tumor blood supply assessment for HCC after TACE than CT and has important clinical value.

Key words: CT, MRI, Subtraction, DSA, TACE

图1 致密结节状沉积：肝实质内见多发碘油沉积灶，碘油在结节内均匀分布，基本填充结节

图2 斑片状沉积：肝右叶见巨大碘油沉积灶，碘油在肿块内分布不均匀

表1 CT、MR及DSA发现病灶的阳性率[n(%)]

项目		n	CT	MR	DSA
全部病灶		126	10(7.94)	116(92.06)	107(89.68)
碘油分布类型		?	?	?	?
?	致密结节状沉积	113	1(0.88)	105(92.92)	104(91.15)
?	斑片状沉积	13	9(69.23)	11(84.62)	7(76.92)
结节类型		?	?	?	?
?	大结节(≥2 cm)	18	7(38.89)	16(88.89)	13(83.33)
?	小结节(<2 cm)	108	3(2.78)	100(92.59)	102(90.74)
病灶位置		?	?	?	?
?	肝左叶	36	1(2.78)	31(86.11)	38(83.33)
?	肝右叶	90	9(0.10)	85(94.44)	85(92.22)

表1 CT、MR及DSA发现病灶的阳性率[n(%)]

项目		n	CT	MR	DSA
全部病灶		126	10(7.94)	116(92.06)	107(89.68)
碘油分布类型		?	?	?	?
?	致密结节状沉积	113	1(0.88)	105(92.92)	104(91.15)
?	斑片状沉积	13	9(69.23)	11(84.62)	7(76.92)
结节类型		?	?	?	?
?	大结节(≥2 cm)	18	7(38.89)	16(88.89)	13(83.33)
?	小结节(<2 cm)	108	3(2.78)	100(92.59)	102(90.74)
病灶位置		?	?	?	?
?	肝左叶	36	1(2.78)	31(86.11)	38(83.33)
?	肝右叶	90	9(0.10)	85(94.44)	85(92.22)

图3 肝实质内多发碘油致密沉积结节, CT增强扫描动脉期(A)肝实质内未见明确异常强化灶,CT增强扫描门静脉(B)难以明确是否有HCC复发。MR增强扫描动脉期减影(C)可见肝实质内见多发强化结节, DSA(D)亦证实为HCC复发

图4 肝右叶见一巨大斑片状碘油沉积肿块, CT增强扫描动脉期(A)及门静脉(B)未能明确结节是否有血供。MR增强扫描动脉期减影(C)可见肿块边缘仍有丰富的血供, DSA(D)亦证实有血供

表2 CT、MR对结节的血供判断的比较

分类	组别	χ²值	P值	灵敏度（%）	特异度（%）	假阳性率（%）	假阴性率（%）	正确指数	阳性似然比	阴性似然比	符合率（%）
全部病灶	CT/DSA	94.450	<0.001	6.2	76.0	23.1	93.8	0.02	0.27	1.22	13.5
全部病灶	MR/DSA	?	0.375	99.1	69.2	30.8	0.9	0.68	3.22	0.01	96.0
致密结节	CT/DSA	100.010	<0.001	1.0	100.0	0	99.0	0.01	0.01	0.99	9.7
致密结节	MR/DSA	?	0.625	99.0	70.0	30.0	1.0	0.69	3.30	0.01	96.5
斑片状沉积	CT/DSA	N	1.000	60.0	0	100.0	40.0	0.04	0.60	0.86	46.2
斑片状沉积	MR/DSA	?	1.000	100.0	66.7	33.3	0	0.67	3.00	0.00	92.3
大结节	CT/DSA	N	0.021	40.0	66.7	33.3	60.0	0.03	1.20	0.90	44.4
大结节	MR/DSA	?	1.000	100.0	66.7	33.3	0	0.67	3.00	0.00	94.4
小结节	CT/DSA	89.253	<0.001	1.0	80.0	20.0	99.0	0.01	0.05	1.24	8.3
小结节	MR/DSA	?	0.625	99.0	70.0	30.0	1.0	0.69	3.30	0.01	96.3
肝左叶	CT/DSA	25.290	<0.001	0	83.3	16.7	100.0	0.02	0.01	1.20	13.9
肝左叶	MR/DSA	?	1.000	100.0	83.3	16.7	0	0.83	6.00	0.00	97.2
肝右叶	CT/DSA	68.321	<0.001	8.4	71.4	28.6	91.6	0.02	0.30	1.28	13.3
肝右叶	MR/DSA	?	0.625	98.8	57.1	42.9	1.2	0.56	2.31	0.02	95.6

表2 CT、MR对结节的血供判断的比较

分类	组别	χ²值	P值	灵敏度（%）	特异度（%）	假阳性率（%）	假阴性率（%）	正确指数	阳性似然比	阴性似然比	符合率（%）
全部病灶	CT/DSA	94.450	<0.001	6.2	76.0	23.1	93.8	0.02	0.27	1.22	13.5
全部病灶	MR/DSA	?	0.375	99.1	69.2	30.8	0.9	0.68	3.22	0.01	96.0
致密结节	CT/DSA	100.010	<0.001	1.0	100.0	0	99.0	0.01	0.01	0.99	9.7
致密结节	MR/DSA	?	0.625	99.0	70.0	30.0	1.0	0.69	3.30	0.01	96.5
斑片状沉积	CT/DSA	N	1.000	60.0	0	100.0	40.0	0.04	0.60	0.86	46.2
斑片状沉积	MR/DSA	?	1.000	100.0	66.7	33.3	0	0.67	3.00	0.00	92.3
大结节	CT/DSA	N	0.021	40.0	66.7	33.3	60.0	0.03	1.20	0.90	44.4
大结节	MR/DSA	?	1.000	100.0	66.7	33.3	0	0.67	3.00	0.00	94.4
小结节	CT/DSA	89.253	<0.001	1.0	80.0	20.0	99.0	0.01	0.05	1.24	8.3
小结节	MR/DSA	?	0.625	99.0	70.0	30.0	1.0	0.69	3.30	0.01	96.3
肝左叶	CT/DSA	25.290	<0.001	0	83.3	16.7	100.0	0.02	0.01	1.20	13.9
肝左叶	MR/DSA	?	1.000	100.0	83.3	16.7	0	0.83	6.00	0.00	97.2
肝右叶	CT/DSA	68.321	<0.001	8.4	71.4	28.6	91.6	0.02	0.30	1.28	13.3
肝右叶	MR/DSA	?	0.625	98.8	57.1	42.9	1.2	0.56	2.31	0.02	95.6

1	Minami Y, Kudo M. Therapeutic response assessment of transcatheter arterial chemoembolization for hepatocellular carcinoma: ultrasonography, CT and MR imaging[J]. Oncology, 2013, 84 Suppl 1: 58-63.
2	Rofsky NM, Lee VS, Laub G, et al. Abdominal MR imaging with a volumetric interpolated breath-hold examination[J]. Radiology, 1999, 212(3): 876-884.
3	Lee VS, Lavelle MT, Rofsky NM, et al. Hepatic MR imaging with a dynamic contrast-enhanced isotropic volumetric interpolated breathhold examination: feasibility, reproducibility, and technical quality[J]. Radiology, 2000, 215(2): 365-372.
4	Yu JS, Kim YH, Rofsky NM. Dynamic subtraction magnetic resonance imaging of cirrhotic liver: assessment of high signal intensity lesions on nonenhanced T1-weighted images[J]. J Comput Assist Tomogr, 2005, 29(1): 51-58.
5	el-Serag HB. Epidemiology of hepatocellular carcinoma[J]. Clin Liver Dis, 2001, 5(1): 87-107.
6	Schafer DF, Sorrell MF. Hepatocellular carcinoma[J]. Lancet, 1999, 353(9160): 1253-1257.
7	Yamada R, Sato M, Kawabata M, et al. Hepatic artery embolization in 120 patients with unresectable hepatoma[J]. Radiology, 1983, 148(2): 397-401.
8	Ohishi H, Uchida H, Yoshimura H, et al. Hepatocellular carcinoma detected by iodize doil. use of anticancer agents[J]. Radiology, 1985, 154(1): 25-29.
9	Takayasu K, Shima Y, Muramatsu Y, et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents[J]. Radiology, 1987, 163(2): 345-351.
10	Matsui O, Kadoya M, Yoshikawa J, et al. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization[J]. Radiology, 1993, 188(1): 79-83.
11	Takayasu K. Transarterial chemoembolization for hepatocellular carcinoma over three decades: current progress and perspective[J]. Jpn J Clin Oncol, 2012, 42(4): 247-255.
12	Ikeda K, Kumada H, Saitoh S, et al. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma: an analysis by the Cox proportional hazard model[J]. Cancer, 1991, 68(10): 2150-2154.
13	Yamanaka K, Hatano E, Kitamura K, et al. Early evaluation of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma[J]. J Gastroenterol, 2012, 47(3): 343-346.
14	Kudo M. Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy[J]. Liver Cancer, 2012, 1(2): 62-70.
15	Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version[J]. Dig Dis, 2011, 29(3): 339-364.
16	Kudo M, Kubo S, Takayasu K, et al. Liver Cancer Study Group of Japan (Committee for Response Evaluation Criteria in Cancer of the Liver): Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 revised version) [J]. Hepatol Res, 2010, 40(7): 686-692.
17	European Association for the Study of the Liver, European Organization for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2012, 56(4): 908-943.
18	Imaeda T, Yamawaki Y, Seki M, et al. Lipiodol retention and massive necrosis after Lipiodol-chemoembolization of hepatocellular carcinoma: correlation between computed tomography and histopathology[J]. Cardiovasc Intervent Radiol, 1993, 16(4): 209-213.
19	Takayasu K, Arii S, Matsuo N, et al. Comparison of CT findings with resected specimens after chemonmbolization with iodized oil for hepatocellular carcinoma[J]. AJR Am J Roentogenol, 2000,175(3): 699-704.
20	Okumura E, Sanada S, Suzuki M, et al. Effectiveness of temporal and dynamic subtraction images of the liver for detection of small HCC on abdominal CT images: comparison of 3D nonlinear image-warping and 3D global-matching techniques[J]. Radiol Phys Technol, 2011, 4(2): 109-120.
21	段阳, 马红丽, 丁世斌, 等. 分析不同阅片者解读三维高分辨力增强磁共振减影图像的一致性[J]. 中国介入影像与治疗学, 2013, 10(4): 239-242.
22	Minardi LT, Passera KM, Lucesoli A, et al. A method for dynamic subtraction MR imaging of the liver[J]. BMC Med Imaging, 2006, 6(1): 5.
23	段阳, 杨本强, 丁世斌, 等. 3D高分辨率MR增强减影探测脑转移瘤可行性和重复性研究[J/CD]. 中华临床医师杂志:电子版, 2013, 7(1): 385-387.
24	杨本强, 段阳, 陶黎, 等. VIBRANT动态增强MRI及其减影对乳腺癌血供的研究[J].磁共振成像, 2011, 2(2): 129-134.
25	张禹, 骆祥伟, 莫子, 等. 三维高时间分辨率MR血管减影成像诊断四肢软组织血管瘤[J]. 中国介入影像与治疗学, 2012, 9(8):609-613.

[1]	韩戟, 杨力, 陈玉. 腹部形态CT参数与完全腹腔镜全胃切除术术中失血量的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 88-91.
[2]	张腾花, 尚培中, 王晓梅, 李晓武, 王金, 苗建军, 刘冰. 外伤性脾破裂三阶梯分层治疗策略[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 510-512.
[3]	谢汶歆, 马乐, 刘晔, 曹晓明, 张万春. 前列腺特异性膜抗原PET/CT在肾癌诊疗中的应用价值[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 514-519.
[4]	江杰, 沈城, 潘永昇, 陈新风, 刘振民, 朱华, 郑兵. 尿酸结石的危险因素分析及双能量CT特征研究[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(04): 361-365.
[5]	钱春蕊, 周燕, 张晶, 蔡笃财, 门慧, 王松海, 黎莉, 邢龙. 高分辨率CT 与多层螺旋CT 在肺结节及早期肺癌中的应用[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 827-830.
[6]	郑大雯, 王健东. 胆囊癌辅助诊断研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 769-773.
[7]	池彬, 魏梁锋, 王守森. CT扫描结合三维可视化技术在腰椎管狭窄症后路显微通道手术前定位的应用[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(04): 220-225.
[8]	李刚, 潘晓帆, 田雪, 刘路路. CT灌注成像参数及血栓弹力图对急性前循环脑梗死早期神经功能恶化的预测价值分析[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(04): 226-232.
[9]	王芳, 刘达, 左智炜, 盛金平, 陈庭进, 蒋锐. 定量CT与双能X线骨密度仪对骨质疏松诊断效能比较的Meta分析[J/OL]. 中华老年骨科与康复电子杂志, 2024, 10(06): 363-371.
[10]	甘曦, 廖鑫. 胃癌旁肿瘤沉积与CT影像学特征、血清指标及病理特征的关联性分析[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 422-425.
[11]	丛黎, 马林, 陈旭, 李文文, 张亮亮, 周华亭. 改良CT严重指数联合炎症指标在重症急性胰腺炎患者胰腺感染预测及预后评估中的研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 432-436.
[12]	刘伟, 高续, 谢玉海, 蒋哲, 刘士成. 基于增强CT影像组学模型在预测急性胰腺炎复发中的应用价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(04): 348-354.
[13]	李金星, 陈志宏, 孙铭均, 孙岩岩, 党树伟, 李广恩, 彭书奇, 付大伟, 李宏伟, 李国东. 基于多层螺旋CT 的腹腔干解剖变异与新分型研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 756-763.
[14]	杨松林, 黄仕豪, 王丽珠, 李禧萌, 邹飞翔, 李坤炜, 梁明柱, 陈炳辉. 良性肺结节生长变化的影像学评价[J/OL]. 中华介入放射学电子杂志, 2024, 12(04): 344-350.
[15]	黎东城, 陈涛, 李新春, 周嘉璇, 包盈莹, 俞家熙, 万齐. MR 弥散加权成像与HRCT 在肺部病变良恶性鉴别中的诊断效能对比[J/OL]. 中华诊断学电子杂志, 2024, 12(04): 249-253.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Application of non rigid 3D-registration for accurate subtraction of dynamic liver MR imaging technique in tumor blood supply assessment for hepatocellular carcinoma after transarterial chemoembolization

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Application of non rigid 3D-registration for accurate subtraction of dynamic liver MR imaging technique in tumor blood supply assessment for hepatocellular carcinoma after transarterial chemoembolization